Cardiome Pharma Receives New Coverage from Analysts at R. F. Lafferty (CRME)
Research analysts at R. F. Lafferty initiated coverage on shares of Cardiome Pharma (NASDAQ:CRME) in a report released on Tuesday, Analyst RN reports. The firm set a “buy” rating and a $9.00 price target on the stock. R. F. Lafferty’s price target suggests a potential upside of 47.54% from the company’s current price.
Shares of Cardiome Pharma (NASDAQ:CRME) traded up 0.98% during mid-day trading on Tuesday, hitting $6.16. The stock had a trading volume of 14,327 shares. Cardiome Pharma has a 52 week low of $1.60 and a 52 week high of $7.15. The stock’s 50-day moving average is $6.13 and its 200-day moving average is $3.73. The company has a market cap of $76.8 million and a P/E ratio of 3.87.
Cardiome Pharma (NASDAQ:CRME) last announced its earnings results on Wednesday, November 6th. The company reported ($0.29) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.21) by $0.08. During the same quarter in the prior year, the company posted ($1.10) earnings per share. On average, analysts predict that Cardiome Pharma will post $0.71 earnings per share for the current fiscal year.
A number of other analysts have also recently weighed in on CRME. Analysts at Canaccord Genuity raised their price target on shares of Cardiome Pharma from $4.50 to $5.50 in a research note to investors on Wednesday, November 20th. They now have a “hold” rating on the stock. Finally, analysts at TheStreet upgraded shares of Cardiome Pharma from a “sell” rating to a “hold” rating in a research note to investors on Monday, October 14th.
Cardiome Pharma Corp. (NASDAQ:CRME) is a life sciences company focused on developing drugs to treat or prevent cardiovascular diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.